Search

Disability Inclusion at Work: Top Score | Boehringer Ingelheim US

Click here to read more on Boehringer Ingelheim receiving a 100 score with Disability:IN’s “Best Place to Work for Disability Inclusion” for the 5th year!

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

A legacy in the making: Working together to spark meaningful change

Discover Jim’s passion for being an advocate for meaningful causes.

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Shelter Bowl: These pets looking for a new home were the big winners

Dogs and cats in a pair of shelters were met with generous donations – and some footballs - thanks to a program committed to improving their future and well-being.

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many

Are combination therapies the answer to battling KRAS cancers?

Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

The Urgency for Heart Failure Research and New Treatment Options

How Simulation is Changing the Game in Biotherapeutic Drug Development

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

From the archives: Maria Plum’s story as a pioneer of her time

Maria Plum was one of the first female lawyers in Germany, and she served as legal counselor for our company starting in the 1930s. Read account of her story written by Katrin Lege, Head of the Boehringer Ingelheim Company Archives, who discovered details

Volunteering to Strengthen the Human-Animal Bond

Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management